Abstract
Aim:Evaluate the clinical effectiveness of platelet-rich plasma as a treatment for lichen sclerosus.Methods:A systematic review was performed. The electronic databases PubMed, Ovid MEDLINE®, Web of Science, Cochrane, clinicaltrials.gov were used to identify case studies, case series, prospective uncontrolled, and randomized controlled studies published between 1946 and April 21, 2021. Six prospective uncontrolled studies, one randomized double-blind prospective study, and one case report were included.Results:Platelet-rich plasma treatment was subjectively reported to improve quality of life, but objective measures demonstrating treatment efficacy were not observed. In addition, platelet-rich plasma preparation and administration between studies lacked standardization.Conclusion:Platelet-rich plasma may be used for symptomatic adjuvant treatment of lichen sclerosus, though additional double-blind controlled studies with standardized platelet-rich plasma protocols are needed to better characterize the efficacy of platelet-rich plasma.
Highlights
Lichen sclerosus (LS) is a chronic inflammatory dermatosis characterized by ivory-white patches with surface wrinkling due to epidermal atrophy, which may display areas of hemorrhage or scar-like changes
The aim of this review is to identify, critically assess and synthesize available scientific evidence on the safety and clinical efficacy of platelet-rich plasma (PRP) for the treatment of LS
Lichen sclerosus diagnosis was established with histopathology (H&E) for 6 studies; histopathology (H&E) combined with colposcopy for 1 study, and not reported for the remaining studies
Summary
Lichen sclerosus (LS) is a chronic inflammatory dermatosis characterized by ivory-white patches with surface wrinkling due to epidermal atrophy, which may display areas of hemorrhage or scar-like changes. LS commonly affects the anogenital region in males and females [Figures 1 and 2], extragenital presentations occur[1]. For topical steroid treatment-resistant LS, alternate topical, intralesional and systemic therapies are utilized, i.e., topical calcineurin inhibitors, topical and systemic retinoids, intralesional corticosteroid injection, systemic immunosuppressants, and phototherapy. These second- and third-line therapies can be associated with poor initial response, resistance over time, and/or adverse drug effects. Autologous platelet-rich plasma (PRP) is being explored as a treatment for LS
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
